The companies’ CAR-T seemed to cause fewer movement disorders in a multiple myeloma trial than J&J's Carvykti has in other ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

BMS third quarter revenues increased 8 percent to $11.90 billion, with its growth portfolio now making up half of total revenues.

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

Electric vehicle battery prices are likely to decline by nearly 50% by 2026, driven by technological advancements and falling metal costs. This… Taiwan Semiconductor Manufacturing Company (TSMC) is ...

Needham raised the firm’s price target on Arcellx (ACLX) to $96 from $81 and keeps a Buy rating on the shares. The firm updated its ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

Bristol Myers Squibb), or idecabtagene vicleucel (Abecma; Bristol Myers Squibb). Approximately 80% of patients received the therapies for lymphoma. Overall, 85% of all patients had previously ...